We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+17.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$41.9M
Cap. Flow %
2.06%
Top 10 Hldgs %
54.88%
Holding
72
New
11
Increased
1
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$19.9M
2
QURE icon
uniQure
QURE
+$14.5M
3
NRIX icon
Nurix Therapeutics
NRIX
+$12.8M
4
APGE icon
Apogee Therapeutics
APGE
+$8.58M
5
TIL icon
Instil Bio
TIL
+$8.37M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$12.7M
2
ALLO icon
Allogene Therapeutics
ALLO
+$8.97M
3
NKTX icon
Nkarta
NKTX
+$8.97M
4
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.66M
5
PRLD icon
Prelude Therapeutics
PRLD
+$3.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
26
Kymera Therapeutics
KYMR
$9.52B
$21.3M 1.05%
+450,000
New +$19.9M
SYRE icon
27
Spyre Therapeutics
SYRE
$8.7B
$20.5M 1.01%
696,480
– –
KURA icon
28
Kura Oncology
KURA
$964M
$19.5M 0.96%
1,000,000
– –
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
$18.4M 0.9%
1,590,000
– –
NKTX icon
30
Nkarta
NKTX
$186M
$18.2M 0.89%
4,029,606
-1,577,744
-28% -$8.97M
ORIC icon
31
Oric Pharmaceuticals
ORIC
$1.11B
$17.8M 0.87%
1,732,571
– –
GPCR icon
32
Structure Therapeutics
GPCR
$3.45B
$17.6M 0.86%
400,000
– –
FATE icon
33
Fate Therapeutics
FATE
$324M
$17.4M 0.85%
4,960,910
-3,255,000
-40% -$12.7M
ELVN icon
34
Enliven Therapeutics
ELVN
$3.8B
$17.1M 0.84%
671,358
– –
REPL icon
35
Replimune Group
REPL
$859M
$16.8M 0.83%
1,536,341
– –
DAWN
36
DELISTED
Day One Biopharmaceuticals
DAWN
$16.6M 0.81%
1,189,943
– –
CGEM icon
37
Cullinan Oncology
CGEM
$1.09B
$15.2M 0.75%
907,895
+250,000
+38% +$4.43M
ARVN icon
38
Arvinas
ARVN
$517M
$15M 0.74%
608,614
– –
CLYM
39
Climb Bio
CLYM
$727M
$13.3M 0.65%
2,603,190
– –
RLAY icon
40
Relay Therapeutics
RLAY
$4.34B
$12.9M 0.63%
1,819,132
– –
NRIX icon
41
Nurix Therapeutics
NRIX
$2.4B
$12.7M 0.62%
+563,067
New +$12.8M
PRTA icon
42
Prothena Corp
PRTA
$453M
$11.5M 0.57%
690,000
– –
QURE icon
43
uniQure
QURE
$2.77B
$11M 0.54%
+2,225,000
New +$14.5M
APGE icon
44
Apogee Therapeutics
APGE
$10.1B
$10.5M 0.52%
+179,000
New +$8.58M
OLMA icon
45
Olema Pharmaceuticals
OLMA
$1B
$7.76M 0.38%
650,000
– –
IOVA icon
46
Iovance Biotherapeutics
IOVA
$2.23B
$7.04M 0.35%
750,000
– –
IPSC icon
47
Century Therapeutics
IPSC
$406M
$6.67M 0.33%
3,900,000
-1,001,603
-20% -$1.96M
JSPR icon
48
Jasper Therapeutics
JSPR
$24.8M
$6.58M 0.32%
350,000
– –
SANA icon
49
Sana Biotechnology
SANA
$877M
$6.43M 0.32%
1,545,000
– –
TERN
50
DELISTED
Terns Pharmaceuticals
TERN
$6.27M 0.31%
+752,000
New +$6.19M
1
2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Boxer Capital held 72 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Boxer Capital's Q3 2024 filing shows 11 new, 1 increased, 5 reduced and 4 closed positions. Its largest new stake was Kymera Therapeutics: 450,000 shares worth $21.3M. The largest sale was Fate Therapeutics, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Boxer Capital's largest Q3 2024 buy was Kymera Therapeutics: 450,000 shares worth $21.3M.
  • Boxer Capital added most to Cullinan Oncology in Q3 2024, an estimated $4.43M increase.
  • Boxer Capital's biggest Q3 2024 reduction was Fate Therapeutics, cutting an estimated $12.7M.
  • Boxer Capital fully exited Allogene Therapeutics in Q3 2024, selling an estimated $8.97M.
  • Boxer Capital's ten largest holdings make up 55% of its $2.04B portfolio in Q3 2024.
  • Boxer Capital opened 11 new positions and closed 4 in Q3 2024.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q3 2024, filed 14 Nov 2024.